Evidence map›Paper›PMID 33293381›Full record

ArticlemBio2020

The Key Glycolytic Enzyme Phosphofructokinase Is Involved in Resistance to Antiplasmodial Glycosides.

Gillian M Fisher, Simon A Cobbold, Andrew Jezewski, Emma F Carpenter, Megan Arnold, Annie N Cowell, Erick T Tjhin, Kevin J Saliba, Tina S Skinner-Adams, Marcus C S Lee and 5 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Systematic in vitro evolution inScience (New York, N.Y.) · 2024
    Article
  6. Article
  7. Photodynamic Inactivation in agriculture: combating fungal phytopathogens resistant to conventional treatment.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. New targets for antimalarial drug discovery.Current opinion in microbiology · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Gillian M FisherGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia.
Simon A CobboldUniversity of Melbourne, Victoria, Australia.
Andrew JezewskiWashington School of Medicine, St. Louis, Missouri, USA.
Emma F CarpenterWellcome Sanger Institute, Cambridge, United Kingdom.ORCID 0000-0002-1911-6842
Megan ArnoldGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia.
Annie N CowellUniversity of California, San Diego, San Diego, California, USA.
Erick T TjhinThe Australian National University, Canberra, Australia.ORCID 0000-0003-1711-0815
Kevin J SalibaThe Australian National University, Canberra, Australia.ORCID 0000-0003-3345-8440
Tina S Skinner-AdamsGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia.ORCID 0000-0001-7011-3850
Marcus C S LeeWellcome Sanger Institute, Cambridge, United Kingdom.
Audrey Odom JohnChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-8395-8537
Elizabeth A WinzelerUniversity of California, San Diego, San Diego, California, USA.
Malcolm J McConvilleUniversity of Melbourne, Victoria, Australia.ORCID 0000-0002-7107-7887
Sally-Ann Poulsen *Griffith Institute for Drug Discovery, Griffith University, Queensland, Australia.
Katherine T Andrews *Griffith Institute for Drug Discovery, Griffith University, Queensland, Australia k.andrews@griffith.edu.au.ORCID 0000-0002-1591-8979
Griffith University · AUAustralian National University · AUThe University of Melbourne · AUUniversity of California San Diego · USWellcome Sanger Institute · GBChildren's Hospital of Philadelphia · USWashington University in St. Louis · US

Funding

TRAINING IN MECHANISMS OF PARASITISMT32AI007511 · NIAID · UNIVERSITY OF IOWA · PI BUTLER, NOAH SULLIVAN, WEBER, MARY · 1996 to 2025
$8.1M
MEP pathway resistance in Plasmodium falciparumR01AI103280 · NIAID · WASHINGTON UNIVERSITY · PI Audrey Ragan Odom John · 2013 to 2026
$5.5M
Discovery of long-acting, chemoprotective antimalarial compoundsR01AI152533 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2020 to 2024
$3.5M
TARGETING ISPC TO TREAT MALARIAR21AI123808 · NIAID · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2016 to 2017
$440k
NIAID NIH HHS R01 AI103280NIAID NIH HHS R01 AI152533NIAID NIH HHS R21 AI123808NIAID NIH HHS T32 AI007511
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AllelesAntimalarialsDose-Response Relationship, DrugDrug ResistanceErythrocytesGlycolysisGlycosidesMetabolomicsModels, MolecularMolecular StructureParasitic Sensitivity TestsPhosphofructokinasesPlasmodium falciparumPolymorphism, Single NucleotideProtein ConformationStructure-Activity RelationshipAntimalarialsGlycosidesPhosphofructokinasesdrug resistance mechanismsdrug targetsglycolysismetabolic regulationPlasmodium falciparum

Identifiers

PMID33293381
PMCPMC7733947
OpenAlexW3112118926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.